Dr Reddy’s Laboratories Ltd has launched Bupropion Hydrochloride Extended-Release Tablets a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) tablets in the US market.
According to a release issued by the Hyderabad-based company here on Wednesday, the Wellbutrin XL brand and generic had US sales of approximately $754 million for the most recent twelve months ending in July 2017 according to IMS Health. Wellbutrin XL is a trademark of GlaxoSmithKline LLC.
Dr Reddy’s scrip lost 0.70 per cent and was trading at Rs 2,193.05 on the Bombay Stock Exchange on Wednesday